Pre-hospital use of direct oral anticoagulants agents is associated with a lower risk of major bleeding events in critically ill patients: A single academic center experience

The last decade has witnessed significant advancements in direct oral anticoagulants (DOACs), transforming the landscape of anticoagulation therapy. Dabigatran was the first DOAC to gain approval in 2011 by the Food and Drug Administration (FDA).1 Apixaban, rivaroxaban, edoxaban and betrixaban soon followed. Randomized controlled trials have demonstrated the noninferiority of DOACs to warfarin for stroke prevention in nonvalvular atrial fibrillation and treatment of venous thromboembolism.1 –5 Based on the robust evidence, clinical practice guidelines strongly recommend using DOACs over warfarin for various cardiovascular indications.
Source: Heart and Lung - Category: Intensive Care Authors: Source Type: research